Navigation Links
New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out-of-Pocket Costs Not Filling Prescriptions
Date:6/17/2009

Avoiding medications may adversely affect patient care and increase health care costs

ST. PAUL, Minn., June 17 /PRNewswire/ -- One in four multiple sclerosis (MS) patients are declining to fill their prescriptions likely due to high out-of-pocket costs, according to new research conducted by pharmacy benefits manager Prime Therapeutics (Prime). The study found that patients with an out-of-pocket expense greater than $250 were seven times more likely to decline to fill their prescription than patients with an out-of-pocket cost of $100 or less. The study concluded that this increase in the number of patients who decline to fill their MS specialty prescriptions and do not continue taking the necessary MS medications may adversely affect long term patient care.

According to the study, the majority of individuals had an out-of-pocket expense of $150 or less and their decline to fill rate was 5.8 percent. For individuals with an out-of-pocket expense of greater than $150 the decline to fill rate was 27.0 percent.

"Specialty pharmacy costs are rising and insurers are focusing on ways to best manage costs, including increasing out-of-pocket costs for members," said Patrick Gleason, PharmD, FCCP, BCPS, lead author and Director of Clinical Outcomes Assessment at Prime Therapeutics. "Our research suggests members who pay high out-of-pocket costs are declining to fill their prescription. Patients who aren't taking their medications face serious medical and health complications, which could result in substantial medical or hospitalization expenses for both the patient and health insurer. Health insurers should consider member cost and the impact it has on adherence when designing specialty pharmacy benefits. "

Multiple sclerosis specialty medications (Avonex(R), Rebif(R), Betaseron(R) or Copaxone(R)) have a typical average wholesale price of $2,500 per month supply, $30,000 annually. Due to the potential large member expense for this specialty drug class, Prime designed the study to examine whether an association existed between declining to fill and out-of-pocket expenses. The study considered a member as "declining to fill" whenever there was a reversed claim for a MS specialty medication and no paid claims for that medication during the following 90 days. The study looked at a database of seven million members from eight commercial Blue Cross and Blue Shield plans who presented a new MS medication prescription to be filled at the pharmacy.

Prime Therapeutics LLC is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.7 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minn., Prime Therapeutics is collectively owned by 11 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study Shows Increases in Working After 65 and Using Commercial Insurance
2. Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity
3. AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure
4. Study Refutes Depression Gene Finding
5. Providing health insurance for US children would be cheaper than expected, study says
6. Study finds autistics better at problem-solving
7. Cannabis alters human DNA -- new study
8. HPV Vaccine Acceptability Study Announces Results
9. MUHC researcher awarded $500,000 to study pathogenesis of infectious disease
10. HealthLeaders-InterStudy Launches Pharmacy Benefit Evaluator
11. Scientific Study Makes it Possible to Measure Connection Between People
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology: